Genocea Biosciences Inc. buy melinda
Summary
This prediction ended on 30.01.18 with a price of €7.40. The price of Genocea Biosciences Inc. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -26.01%. melinda has 50% into this predictionGenocea Biosciences (Symbol GNCA) (WKN A2PK76) is a publicly traded, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel vaccines and immunotherapies for various infectious diseases and cancer. With a unique approach to unlocking the power of T-cells in rapid vaccine and immunotherapy discovery, the company has established a robust pipeline targeting a wide spectrum of viral, bacterial, and parasitic diseases as well as oncology indications. Notable programs include GEN-003 for genital herpes and GEN-009, an innovative and personalized neoantigen cancer vaccine. Listed on the Nasdaq stock exchange, Genocea is dedicated to improving patient outcomes through cutting-edge research, expertise in immune targeting, and a strong commitment to scientific innovation.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Genocea Biosciences Inc. | - | - | - | - |
iShares Core DAX® | 1.665% | 0.362% | 17.556% | 15.301% |
iShares Nasdaq 100 | -0.475% | -3.195% | 26.812% | 36.536% |
iShares Nikkei 225® | 2.620% | 1.174% | 17.273% | 10.880% |
iShares S&P 500 | -0.091% | -1.597% | 24.739% | 36.919% |
Comments by melinda for this prediction
In the thread Genocea Biosciences Inc. diskutieren
$
Stopped prediction by melinda for Genocea Biosciences Inc.
Genocea Biosciences Inc.
11.04.22
11.04.23
12.04.23
Genocea Biosciences Inc.
08.02.21
08.02.22
11.05.21
Genocea Biosciences Inc.
29.09.17
30.01.18
30.01.18